CN1750824A - 用于治疗局部缺血性损伤的4－[(2,4－二氯－5－甲氧苯基)氨基]－6－烷氧基－3－氰基喹琳类 - Google Patents

用于治疗局部缺血性损伤的4－[(2,4－二氯－5－甲氧苯基)氨基]－6－烷氧基－3－氰基喹琳类 Download PDF

Info

Publication number
CN1750824A
CN1750824A CNA2004800046743A CN200480004674A CN1750824A CN 1750824 A CN1750824 A CN 1750824A CN A2004800046743 A CNA2004800046743 A CN A2004800046743A CN 200480004674 A CN200480004674 A CN 200480004674A CN 1750824 A CN1750824 A CN 1750824A
Authority
CN
China
Prior art keywords
dichloro
amino
methoxyphenyl
methoxy
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800046743A
Other languages
English (en)
Chinese (zh)
Inventor
D·H·博谢利
M·M·扎莱斯卡
F·C·博谢利
K·T·阿恩特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1750824(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1750824A publication Critical patent/CN1750824A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800046743A 2003-02-21 2004-02-19 用于治疗局部缺血性损伤的4－[(2,4－二氯－5－甲氧苯基)氨基]－6－烷氧基－3－氰基喹琳类 Pending CN1750824A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44931603P 2003-02-21 2003-02-21
US60/449,316 2003-02-21

Publications (1)

Publication Number Publication Date
CN1750824A true CN1750824A (zh) 2006-03-22

Family

ID=32927510

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800046743A Pending CN1750824A (zh) 2003-02-21 2004-02-19 用于治疗局部缺血性损伤的4－[(2,4－二氯－5－甲氧苯基)氨基]－6－烷氧基－3－氰基喹琳类

Country Status (19)

Country Link
US (1) US20040229880A1 (https=)
EP (1) EP1594502A1 (https=)
JP (1) JP2006522023A (https=)
KR (1) KR20050102133A (https=)
CN (1) CN1750824A (https=)
AR (1) AR043253A1 (https=)
AU (1) AU2004216235A1 (https=)
BR (1) BRPI0407441A (https=)
CA (1) CA2516418A1 (https=)
CO (1) CO5640114A2 (https=)
CR (1) CR7931A (https=)
EC (1) ECSP055972A (https=)
MX (1) MXPA05008706A (https=)
NO (1) NO20054070L (https=)
RU (1) RU2005129333A (https=)
TW (1) TW200423938A (https=)
UA (1) UA80472C2 (https=)
WO (1) WO2004075898A1 (https=)
ZA (1) ZA200506621B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103772392A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
CN107814769A (zh) * 2016-09-14 2018-03-20 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
CN111646940A (zh) * 2019-03-04 2020-09-11 鲁南制药集团股份有限公司 一种博舒替尼中间体的制备方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680119A1 (en) 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
JP2008517924A (ja) * 2004-10-22 2008-05-29 ワイス 虚血傷害を処置するための４−［（２，４−ジクロロ−５−メトキシフェニル）アミノ］−６−アルコキシ−７−エチニル−３−キノリンカルボニトリル
EP1902029B2 (en) * 2005-07-01 2022-02-16 Wyeth LLC Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
ES2565627T3 (es) * 2010-07-30 2016-04-06 Oncotherapy Science, Inc. Derivados de quinolina e inhibidores de MELK que contienen los mismos
WO2015123758A1 (en) * 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
US20160256457A1 (en) * 2014-06-10 2016-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for treating or preventing acute vascular leak
EP3227276B1 (en) 2014-12-02 2021-09-01 Ignyta, Inc. Combinations for the treatment of neuroblastoma
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
BR112018012255A2 (pt) 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
AU2018302170B2 (en) 2017-07-19 2024-02-29 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
CA2500368A1 (en) * 2002-10-04 2004-04-22 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103772392A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
CN107814769A (zh) * 2016-09-14 2018-03-20 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
CN107814769B (zh) * 2016-09-14 2021-05-07 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
CN111646940A (zh) * 2019-03-04 2020-09-11 鲁南制药集团股份有限公司 一种博舒替尼中间体的制备方法
CN111646940B (zh) * 2019-03-04 2024-01-30 鲁南制药集团股份有限公司 一种博舒替尼中间体的制备方法

Also Published As

Publication number Publication date
ZA200506621B (en) 2008-02-27
JP2006522023A (ja) 2006-09-28
ECSP055972A (es) 2006-01-16
NO20054070L (no) 2005-11-14
CA2516418A1 (en) 2004-09-10
AU2004216235A1 (en) 2004-09-10
KR20050102133A (ko) 2005-10-25
AR043253A1 (es) 2005-07-20
EP1594502A1 (en) 2005-11-16
BRPI0407441A (pt) 2006-01-31
WO2004075898A1 (en) 2004-09-10
TW200423938A (en) 2004-11-16
US20040229880A1 (en) 2004-11-18
CO5640114A2 (es) 2006-05-31
NO20054070D0 (no) 2005-09-01
CR7931A (es) 2006-02-07
RU2005129333A (ru) 2006-01-27
MXPA05008706A (es) 2005-10-05
UA80472C2 (en) 2007-09-25

Similar Documents

Publication Publication Date Title
CN1220682C (zh) 抑制因子Xa的杂环衍生物
CN1253449C (zh) 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
JP6090801B2 (ja) キナーゼ阻害剤としてのアミノキナゾリン
JP6026441B2 (ja) キナーゼ阻害剤としてのアミノキノリン
CN1750824A (zh) 用于治疗局部缺血性损伤的4－[(2,4－二氯－5－甲氧苯基)氨基]－6－烷氧基－3－氰基喹琳类
CN1037898A (zh) 芳族及杂环甲酰胺衍生物抗肿瘤剂的制备
CN1444563A (zh) 喹啉和喹唑啉衍生物
CN1294131C (zh) 新嘧啶化合物
AU2014220300B2 (en) Quinazolines as kinase inhibitors
CN1795195A (zh) 新颖的吡啶并吡嗪及其作为激酶调节剂的用途
CN1409711A (zh) 用作hiv逆转录酶抑制剂的稠合的二氮萘化合物
CN1265098A (zh) 抑制因子xa的杂环衍生物
CN1127498C (zh) 吡啶衍生物、制备吡啶衍生物的方法及其中间体
CN1545513A (zh) 新颖的2h-哒嗪-3-酮衍生物、含有它们的药物组合物和活性成分的制备方法
CN100339379C (zh) 2－吡啶基－6,7,8,9－四氢嘧啶并[1,2－а]嘧啶－4－酮和7－吡啶基－2,3－二氢咪唑并[1,2－а]嘧啶－5（1H）酮衍生物
CN1468224A (zh) 用作α-2拮抗剂的喹啉衍生物
CN1138581A (zh) 取代的联苯磺酰胺类内皮素拮挤剂
CN1684951A (zh) 新的嘧啶胺衍生物及其用途
CN101039944A (zh) 具有cdk1抗增殖活性的1,5－二氮杂萘唑烷酮类
CN1062138A (zh) Hiv反转录酶抑制剂的增效
CN1048242C (zh) 5-氨基-8-甲基-7-吡咯烷喹啉-3-羧酸衍生物及其制造方法和中间体化合物
CN101052634A (zh) 作为vegf受体激酶抑制剂的邻氨基苯甲酰胺吡啶脲
CN1378543A (zh) 具有血管生成抑制活性的取代的哒嗪和稠合的哒嗪
CN1102527A (zh) 末梢血管舒张剂
CN1918148A (zh) 取代的苯并咪唑和它们诱导细胞凋亡的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060322